Results 31 to 40 of about 18,599 (272)

Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2023
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes.
Anca Chelariu-Raicu   +10 more
doaj   +1 more source

Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology
Comprehensive genomic profiling (CGP) and the subsequent discussions in molecular tumor boards (MTBs) are becoming an integral part of personalized cancer care.
Ashkan Adibi   +7 more
doaj   +2 more sources

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

open access: yesmAbs, 2022
Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolizes nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide.
Harshad S. Ugamraj   +19 more
doaj   +1 more source

PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages

open access: yesPathogens, 2023
Aberrant adenosine diphosphate-ribose (ADP)-ribosylation of proteins and nucleic acids is associated with multiple disease processes such as infections and chronic inflammatory diseases. The poly(ADP-ribose) polymerase (PARP)/ADP-ribosyltransferase (ART)
Diego V. Santinelli-Pestana   +3 more
doaj   +1 more source

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2021
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV ...
Alistair McLaren   +3 more
doaj   +1 more source

Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation. [PDF]

open access: yesPLoS ONE, 2009
Poly adenosine diphosphate-ribose polymerase-1 (PARP-1) is a multifunctional enzyme that is involved in two major cellular responses to oxidative and nitrosative (O/N) stress: detection and response to DNA damage via formation of protein-bound poly ...
Ben Buelow   +3 more
doaj   +1 more source

The Critical Role of PARPs in Regulating Innate Immune Responses

open access: yesFrontiers in Immunology, 2021
Poly (adenosine diphosphate-ribose) polymerases (PARPs) are a family of proteins responsible for transferring ADP-ribose groups to target proteins to initiate the ADP-ribosylation, a highly conserved and fundamental post-translational modification in all
Huifang Zhu   +4 more
doaj   +1 more source

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer

open access: yesCase Reports in Oncology, 2023
Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor.
Mana Sekine   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy